It has to be noted that besides HER2-imaging agents, there are currently several new Affibody molecules targeting other cancer-associated receptors, e.g. EGFR [32], IGF-1R [33], PDGF-Rβ [34] and HER3 [35], under development. Here, ERBB3 is linked to cancer.